SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending after a post-earnings sell-off, with the community actively debating whether strong quarterly results and a share buyback are overshadowed by persistent concerns about high stock-based compensation and dilution, amid long-term optimism for AI/AR innovations.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending after its Q4 earnings report, where strong profitability and a strategic shift towards prudent risk management were met with a severe market sell-off due to conservative revenue guidance and prevailing fintech sector weakness. The community is sharply divided, with many calling the stock oversold and deeply undervalued while others express frustration over management's outlook and perceived manipulation.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as it opens its 30,000th store, including a new premium flagship, coinciding with rival Cotti Coffee reportedly ending its aggressive discount strategy. This development is driving community discussions around potential margin expansion and the company's significant undervaluation compared to competitors.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is plummeting after the abrupt departures of its CFO and general counsel amid an SEC accounting investigation, sparking intense community discussion on whether the severe market reaction presents a bargain opportunity or signals deeper issues akin to prior corporate collapses.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is seeing intense discussion around its pivotal role in the AI-nuclear nexus, fueled by its power development partnership with Meta and anticipated DOE plutonium awards, though persistent insider selling and its pre-revenue status are generating fierce debate and price swings.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

Recent exchange listings and extensive utility enhancements for BankrCoin's AI-powered trading agents on the Base ecosystem are driving intense community discussion, with many anticipating significant price discovery despite lingering "pump and dump" concerns.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is actively discussed after its latest earnings report, which saw an EPS beat but a revenue miss largely due to contract transitions and a government shutdown, leading to divided community sentiment with many investors calling the stock's decline an overreaction and a long-term buying opportunity given its substantial backlog in nuclear, space, and defense programs.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending following the FDA's Complete Response Letter for its RGX-121 gene therapy for Hunter syndrome, citing issues with trial design and the use of natural history controls. The community is now intensely discussing the severe financial impact on the company and potential ramifications for its other gene therapy programs and the broader sector.

Haverty Furniture Cos., Inc. engages in the retail of residential furniture and accessories. Its products are Tempur-Pedic, Serta, Stearns and Foster, Beautyrest, and Sealy. The company was founded by James Joseph Haverty in 1885 and is headquartered in Atlanta, GA.

Haverty Furniture Cos., Inc. - Ordinary Shares - Class A

Haverty Furniture (HVT.A) is trending following a notable price jump, sparking significant community excitement and discussion about potential profit opportunities.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending amidst upcoming Q4 earnings and recent partnership announcements, including a new integration with Kikoff and strong speculation around a Hyundai white-label deal, which bulls believe will drive significant growth. However, persistent stock declines, perceived market manipulation by shorts and insiders, and community frustration with CEO Alex Timm's communication have created a highly polarized sentiment, despite the company's reported operational improvements and profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

COMPASS Pathways (NASDAQ:CMPS) Stock Price Down 7.6% - Should You Sell?

COMPASS Pathways (NASDAQ:CMPS) Trading Down 7.6% - Should You Sell...

COMPASS Pathways Target of Unusually High Options Trading (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) saw some unusual options trading on Friday. Investors bought 7,423 call options on the company. This is an increase of 152% compared...

Royal Bank Of Canada Increases COMPASS Pathways (NASDAQ:CMPS) Price Target to $21.00

Royal Bank Of Canada increased their target price on COMPASS Pathways from $16.00 to $21.00 and gave the stock an "outperform" rating in a research note on Friday...

COMPASS Pathways (NASDAQ:CMPS) Trading Down 5.5% - What's Next?

COMPASS Pathways (NASDAQ:CMPS) Trading Down 5.5% - Here's What Happened...

<ul><li>FDA has accepted the company's Investigational New Drug application for COMP360.</li><li>The latest update clears the way for a late-stage Phase 2b/3 clinical trial.</li><li>The company said prior Phase 2 data showed the treatment was generally well tolerated.</li></ul>Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application for COMP360, a drug to treat post-traumatic stress disorder (PTSD). The latest update clears the way for a late-stage Phase 2b/3 clinical trial.The study will evaluate the efficacy, safety, and tolerability of COMP360, with a blinded 12-week phase followed by a long-term open-label extension. The company said prior Phase 2 data showed the treatment was generally well tolerated and delivered rapid, durable symptom improvement.&nbsp;Compass also highlighted ongoing FDA discussions around a potential rolling NDA submission for treatment-resistant depression, with additional Phase 3 data expected in 2026.“PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options. We believe COMP360 has the potential to transform the treatment landscape for PTSD and bring hope to those who need it most,” said Guy Goodwin, Chief Medical Officer at Compass Pathways.<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> was up over 5% in pre-market trading on Wednesday.Earlier this week, Compass Pathways entered its seventh strategic collaboration, partnering with Radial Health, a national network of interventional psychiatry practices.&nbsp;The agreement is aimed at developing scalable care models for COMP360 psilocybin treatment, if approved, across a wide range of U.S. mental health care settings.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for CMPS on Stocktwits turned 'bullish' from 'bearish' a day earlier.&nbsp;<img src="https://news.stocktwits-cdn.com/CMPS_jpg_0a063eb6f2.webp" alt="CMPS.jpg">One user expects the stock to climb to $15 over the next few days.<stembedurl>https://stocktwits.com/macrossluvsrobotech/message/641088236</stembedurl>The stock has gained nearly 60% this year.<a href="https://stocktwits.com/news-articles/markets/equity/why-did-first-solar-stock-fall-5-in-premarket-today/cmxyC2bR4cD">Read also: Why Did First Solar Stock Fall 5% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path

The company highlighted ongoing FDA discussions around a potential rolling NDA submission for treatment-resistant depression, with additional Phase 3 data expected in 2026.

Equity

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA...

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic...

Simplify Asset Management Inc. Purchases Shares of 290,000 COMPASS Pathways PLC Sponsored ADR $CMPS

Simplify Asset Management Inc. acquired a new position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) during the third quarter, according to the company in its most...

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are covering the stock, MarketBeat...

<ul class="summary-bullets"><li>With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at a 15% CAGR to nearly $13 billion by 2035</li><li>&nbsp;Both Compass Pathways and Mind Medicine are positioned to tap a massive unmet need.</li><li>Mind Medicine leads in retail sentiment, cash runway into 2028, and late-stage progress with MM120, while Compass Pathways’ COMP360 could reach the market sooner.</li></ul>After years on the fringes of mainstream medicine, psychedelic drugmakers are suddenly finding themselves in the spotlight.Shares of companies developing psychedelic-based therapies surged this year, buoyed by a gradual softening of regulatory resistance, growing political support, and a string of company-specific catalysts. Positive clinical trial readouts, renewed investor appetite, and a pickup in merger-and-acquisition chatter have all helped fuel momentum across the space.As optimism builds around the therapeutic potential of psychedelics to treat conditions ranging from depression to PTSD, two names have stood out among the pack: Compass Pathways and Mind Medicine. Here’s a closer look at how these two psychedelic high-fliers compare — and what’s driving their rise.<h2 class="st-heading-2">Psychedelics Turn Mainstream</h2>Stymied by regulatory roadblocks, research into hallucinogenic compounds remained largely dormant for decades. However, a gradual regulatory thaw and a growing mental-health crisis have sparked renewed scientific interest. Psychedelics such as psilocybin, MDMA, and LSD are moving into the mainstream of psychological research, backed by robust clinical trials and growing institutional support.&nbsp;The psychedelics drug market is expected to grow at a compounded annual growth rate (CAGR) of 15% to nearly $13 billion in 2035 from $3 billion in 2025,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html">according</a> to Business Research and Consulting Group Roots Analysis.<img src="https://news.stocktwits-cdn.com/Psychedelics_Market_png_7463be0aca.webp" alt="Psychedelics Market.png">Source: Roots AnalysisThe&nbsp;<a href="https://stocktwits.com/symbol/PSIL">AdvisorShares Psychedelics ETF (PSIL)</a> has outperformed the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, which tracks the broader S&amp;P 500 Index.<img src="https://news.stocktwits-cdn.com/PSIL_Vs_SPY_png_168a676f0b.webp" alt="PSIL Vs SPY.png">Source: Koyfin<h2 class="st-heading-2">What Has Turned The Tide?</h2>This class of drugs has received strong backing from high-profile personalities, including Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Martin Makary. Kennedy has previously&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-soars-after-rfk-jr-confirmed-as-hhs-chief/ch5iJvpRH6">advocated</a> for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.As an extension, the FDA has accorded top priority to review MDMA and other psychedelics, even mulling accelerated approval for these drugs.&nbsp;Big pharma name AbbVie announced an agreement to acquire Gilgamesh Pharmaceuticals' novel psychedelic therapy candidate, bretisilocin, in August for up to $1.2 billion, lending credence to this class of medication. Atai, a biotech developing treatments for mental health, merged with Beckley Psytech, bringing Beckley's BPL-003, an investigational therapy for treatment-resistant depression (TRD) and alcohol use disorder (AUD), into its pipeline. ATAI Beckley’s stock has gained 220% this year.<h2 class="st-heading-2">Compass Pathways Vs. Mind Medicine</h2>Mind Medicine stock has returned about 110% year-to-date, compared with the 84% gain for Mind Medicine.<img src="https://news.stocktwits-cdn.com/MNMD_Vs_CMPS_png_35ac2a510a.webp" alt="MNMD Vs CMPS.png">Source: KoyfinThe primary draw for these stocks lies in the sheer size of the market opportunity. In a presentation, Mind Medicine highlighted that roughly 51.5 million adults in the U.S. are affected by mental illness, underscoring the vast and largely underserved demand for effective treatments.Mind Medicines’ lead candidate MM120 orally disintegrating tablet (ODT) is in late-stage trials for major depressive disorder (MDD). Topline data from the study is due in mid-2026. Delving into the upcoming catalysts, CEO Rob Barrow said in the third-quarter earnings release:<blockquote>“We plan to initiate Ascend, our second Phase 3 study in MDD, in mid-2026 and remain focused on advancing toward FDA submissions in both generalized anxiety disorder (GAD) and major depressive disorder (MDD). With multiple anticipated Phase 3 topline data readouts ahead, 2026 is set to be the most significant year in our history to date. ”</blockquote>Mind Medicine reported no revenue and a net loss of $67.3&nbsp;million for the three months ended Sept. 30, 2025. On the other hand, Compass Pathways’ net loss stood at $137.72 million for the September quarter,&nbsp;compared with a loss of $38.50 million a year&nbsp;earlier.London-based Compass Pathways’ lead candidate COMP360, a synthetic formulation of psilocybin that is in late-stage clinical trials for treating mental health conditions, primarily treatment-resistant depression (TRD). CEO Kabir Nath said in the earnings release that the company was moving up the expected launch timing for COMP360 in TRD by 9 to 12 months. The company&nbsp;intends to file for approval by the second half of 2026.&nbsp;<h2 class="st-heading-2">MNMD Vs. CMPS: Cash Position</h2>Mind Medicine has beefed up its cash position with a recent offering. It said its cash, cash equivalents, and investments as of September 30, 2025 ($209.1 million), along with the net proceeds of $242.8 million from the recently completed offering, will be sufficient to fund the operations into 2028. Meanwhile, Compass Pathways had a smaller cash reserve at a comparable point, but the company said it would be enough to fund operating expenses and capital expenditures through 2027.<img src="https://news.stocktwits-cdn.com/Cash_Position_Sufficient_For_Medium_Term_png_e0ea50d775.webp" alt="Cash_Position_Sufficient_For_Medium_Term.png">Source: Fiscal.ai<h2 class="st-heading-2">MNMD Vs. CMPS: How Retail’s Positioned</h2>Retail traders, however, are favorably disposed to Mind Medicine. On Stocktwits, retail sentiment toward the stock has been ‘bullish’ as of early Wednesday.<figure class="image"><img style="aspect-ratio:712/439;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_8_37_12_AM_png_3de00ad9f2.webp" alt="Screenshot 2025-12-24 at 8.37.12 AM.png" width="712" height="439"></figure>Compass Pathways, meanwhile, attracted ‘neutral’ sentiment among retailers, with sentiment showing volatility throughout the year.<figure class="image"><img style="aspect-ratio:721/436;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_8_39_54_AM_png_d4c6176ec9.webp" alt="Screenshot 2025-12-24 at 8.39.54 AM.png" width="721" height="436"></figure>According to Koyfin, the average analyst price target for Mind Medicine stock is $28.67, implying 105% upside potential. All 13 analysts covering the stock have either a ‘Buy’ or a ‘Strong Buy’ rating on the stock. Compass Pathways stock, meanwhile,&nbsp;has 144% upside potential, based on the average price target of $16.82. All but one of the 11 analyst covering the stock has bullish ratings.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-revamps-robotaxi-website-revamp-how-competition-stacks-up/cLesMvuREv3">Tesla Signals Robotaxi Expansion With Website Revamp — Here’s How The Competition Stacks Up</a>

 Creative image of an Hallucinogenic mushroom. (Representative image courtesy of Aitor Diago via Getty Images)

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year?

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CMPS News

CMPSCOMPASS Pathways